rjantz@cooley.com
Rick Jantz focuses on domestic and international transactional tax matters. He has advised public and private companies, private equity funds, financial institutions and non-profit organizations.
Download full bio
X4 Pharmaceuticals in its Exclusive License Agreement with Abbisko Therapeutics
GENFIT SA in its Licensing and Collaboration Agreement with Terns Pharmaceuticals
Vir Biotechnology - $143 Million IPO
Arlo to Partner with Verisure
Reata Pharmaceuticals – $505 Million Follow-On Offering
View all
Tax
Mergers & Acquisitions
New York University School of LawJD, Jacobson Scholar, 2015
University of California, Los AngelesBA, Business Economics2012
California
Summit Healthcare Closes Business Combination With YS Biopharma March 20, 2023
Redx Pharma to Merge With Jounce Therapeutics February 24, 2023
Structure Therapeutics – $185.3 Million IPO February 9, 2023
+1 310 883 6493
Locations